KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Non-Current Liabilities (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $337.3 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 10.04% to $337.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $337.3 million through Dec 2025, up 10.04% year-over-year, with the annual reading at $337.3 million for FY2025, 10.04% up from the prior year.
  • Total Non-Current Liabilities hit $337.3 million in Q4 2025 for CRISPR Therapeutics AG, up from $324.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $394.1 million in Q3 2022 to a low of $144.3 million in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $332.3 million across 5 years, with a median of $345.4 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 145.31% in 2022 and later dropped 11.58% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $345.1 million in 2021, then increased by 4.79% to $361.6 million in 2022, then dropped by 4.37% to $345.8 million in 2023, then decreased by 11.36% to $306.5 million in 2024, then increased by 10.04% to $337.3 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CRSP at $337.3 million in Q4 2025, $324.0 million in Q3 2025, and $314.1 million in Q2 2025.